Confident communication in respiratory medicine
Elion Medical Communications specialises in respiratory writing that turns guideline‑driven science into engaging, easy-to-understand resources. Our team helps researchers, pharmaceutical companies and healthcare professionals explain asthma and chronic obstructive pulmonary disease (COPD) therapies with confidence and clarity.
Leading with experience
For more than a decade, we have supported the launch and growth of therapies and medical devices that aid in the treatment of asthma and chronic obstructive pulmonary disease (COPD) — respiratory diseases that affect millions of people each year. Our writers, editors and project leads work together to translate study data, guideline updates and device features into materials that help bring life-changing treatments to market.
Respiratory communication in line with guidance and best practice
Asthma and COPD care follow clear treatment steps as determined in current reports of the Global Initiative for Asthma (GINA) and the Global Initiative for Chronic Obstructive Lung Disease (GOLD).
In recent years, the treatment of asthma and COPD has shifted towards personalised care. Biologics for severe asthma, once-daily triple therapies for COPD, digital inhalers and patient-monitoring platforms are becoming common in clinical practice. As treatment options expand, so does the need for tailored medical communication. As an established communications partner, Elion helps pharmaceutical brands and healthcare teams promote new therapies through content that reflects current guidance and patient needs.
Respiratory communications in line with guidances and best practice
Asthma and COPD care follow clear treatment steps as determined in current reports of the Global Initiative for Asthma (GINA) and the Global Initiative for Chronic Obstructive Lung Disease (GOLD).
In recent years, the treatment of asthma and COPD has shifted towards personalised care. Biologics for severe asthma, once-daily triple therapies for COPD, digital inhalers and patient-monitoring platforms are becoming common in clinical practice. As treatment options expand, so does the need for tailored medical communication. As an established communications partner, Elion helps pharmaceutical brands and healthcare teams promote new therapies through content that reflects current guidance and patient needs.
Trends in therapies for respiratory diseases
Bronchodilators
Bronchodilators are medicines that help open the airways, making it easier for patients to breathe. They relax the muscles around the lungs, which become tight during asthma or COPD attacks. Different groups of bronchodilators are used for different purposes. Short-acting medications such as salbutamol and ipratropium bromide are used for quick symptom relief. Long-acting medicines, such as salmeterol, formoterol, tiotropium bromide or theophylline, help control symptoms over the long term.
Anti-inflammatory agents
Anti-inflammatory agents reduce airway swelling and inflammation. Inhaled corticosteroids (ICS) such as fluticasone and budesonide are used daily to prevent asthma and COPD flare-ups, whereas systemic corticosteroids such as prednisolone are used during acute attacks. These drugs suppress inflammatory genes, reducing the production of inflammatory proteins and immune cells.
Other treatments include leukotriene receptor antagonists such as montelukast, which blocks inflammatory pathways by preventing leukotrienes from binding to the cysteinyl leukotriene receptor.
Immunomodulatory agents such as methotrexate, sarilumab and tocilizumab are emerging options for chronic or steroid-resistant disease, and work by modulating the immune system to suppress inflammation.
Combination therapies
Combination inhalers deliver two or more medicines in one device. Common combinations include an ICS with a long-acting bronchodilator (long-acting beta-agonist [LABA]) or two bronchodilators such as a LABA with a long-acting muscarinic antagonist (LAMA). Triple therapy, which combines an ICS, a LABA and a LAMA, is often used for patients with severe disease. These combinations improve lung function, reduce the risk of flare-ups and support better treatment adherence by offering a ‘package’ therapy.
Biologics (for severe asthma)
Biologics are advanced therapies used in severe asthma that does not respond well to standard inhalers. These medicines are given by injection and work by targeting the immune system. Omalizumab blocks immunoglobulin E, an antibody that plays a key role in allergic asthma. Mepolizumab and benralizumab block interleukin (IL)-5, which is linked to high eosinophil counts. Dupilumab targets both IL-4 and IL-13 pathways. These targeted therapies help reduce inflammation, lower the need for steroids and prevent serious asthma attacks.
Phosphodiesterase-4 inhibitors (COPD-specific)
Roflumilast is an oral medicine used in patients with severe COPD, especially those who have chronic bronchitis and frequent flare-ups. It works by blocking an enzyme called phosphodiesterase-4. Roflumilast can help prevent worsening symptoms in patients who continue to struggle despite inhaler therapy.
Our work in respiratory diseases
Elion’s team includes skilled medical writers with experience in developing:
- manuscripts for medical journals
- abstracts, posters and oral presentations
- medical affairs slide decks
- interactive training modules
- informative blogs
- patient‑friendly leaflets
- inhaler instruction cards
Respiratory diseases:
- asthma
- COPD
- cystic fibrosis
- pulmonary hypertension
- interstitial lung disease
- idiopathic pulmonary fibrosis
- respiratory syncytial virus infection
- influenza
- pneumonia
Our approach sets us apart
At Elion, we bring leadership and insight to respiratory disease communications, building trusted partnerships with pharmaceutical and healthcare teams.
We deliver accurate, engaging content that aligns with your goals and the latest GINA and GOLD guidance, from concept to completion.
01
Define
Aligning on goals: we begin with a kick-off call and written brief to clarify objectives, timelines, audience, and deliverables. This ensures a shared understanding and smooth project setup.
02
Create
Developing content: we draft clear and engaging content in collaboration with your team. Messaging is grounded in evidence and tailored for your audience.
03
Refine
Reviewing and improving: we edit, fact check and integrate feedback to ensure accuracy, consistency and alignment with industry standards.
04
Enhance
Optimising outputs: we refine visuals, formatting and structure to maximise impact and engagement across all intended channels.
05
Deliver
Finalising and measuring impact: we prepare final deliverables, ready for submission, presentation or distribution. We can also help define success metrics and gather performance insights to inform future projects.
Expertise in respiratory disease writing
At Elion, we work closely with healthcare organisations and pharmaceutical companies.
We understand the challenge of keeping pace with changing guidelines and evolving science in asthma and COPD. Our writers bring experience in biologics, combination therapies, inhaler technologies and more to your communications.
Respiratory diseases FAQs
Asthma and COPD are both chronic conditions that affect the airways.
Asthma is a chronic inflammatory disorder of the airways. It’s marked by reversible airflow obstruction, bronchial hyper‑responsiveness and symptoms such as wheeze, cough and shortness of breath. Asthma affects all ages, though it’s more common in childhood.
COPD is also a chronic, progressive disease characterised by persistent airflow obstruction and tissue destruction. It’s often linked to smoking. Patients experience chronic breathlessness, reduced exercise capacity and recurrent exacerbation.
Correct management strategies and early intervention are vital for treating both conditions.
Our team covers peer‑reviewed manuscripts, congress posters, inhaler‑technique videos and patient‑centred asthma and COPD education leaflets. Our materials speak directly to your audience while maintaining compliance with current GINA and GOLD reports.
In the past decade, Elion has partnered with global respiratory brands to develop a wide range of patient-friendly content, such as leaflets, action plans, inhaler guides and animated explainers. Our materials use clear language and visuals, making complex information accessible for patients of all ages and literacy levels. These materials help patients understand their treatment and feel confident managing their condition.
We support launch teams with the full range of scientific and strategic content from publication plans and slide decks through to training modules. We provide clear, strategic content to support each stage of the process, from briefing to post-launch.
At Elion, we have deep experience in the respiratory space and understand how to align messaging with current guidelines. Our team focuses on practical challenges in asthma and COPD care such as inhaler use, adherence and disease monitoring. A partnership with Elion is based on trust, professionalism and transparency.
We analyse trial results and real-world data to highlight the outcomes that matter most, such as reduced flare-ups, improved lung function and better daily symptom control. Each message is carefully crafted to be scientifically accurate and easy to understand for your target audience.
The time it takes to submit a completed project depends on the project itself. A short slide deck or abstract can reach you within 48-72 hours. Larger packages follow a phased plan that our teams agree with you before starting work. Our writers in New Zealand and Europe hand projects off as the sun sets, so drafts move forward while you sleep. This 24‑hour workflow keeps tight timelines on track and speeds every piece of respiratory medical writing.
